OBJECTIVE: To determine the variability of several clinical outcome measurements commonly used in scleroderma clinical trials. METHODS: Ten researchers, members of a multicenter placebo controlled trial of methotrexate in early diffuse scleroderma, studied the intraobserver and interobserver variability of variables used to assess efficacy in scleroderma trials. RESULTS: For most measures, the variability within an observer was less than that found between observers, and therefore the intraobserver reliability was better than the interobserver reliability. The reliability of the modified Rodnan skin score exceeded the Rodnan skin score. Measures with inherent interpretation such as global assessments and skin scores had more variability than easily performed measurements such as grip strength and oral opening. CONCLUSION: Some of our variability was higher than variability previously reported; this could be due to the large number of examiners and patients in our study.
RCT Entities:
OBJECTIVE: To determine the variability of several clinical outcome measurements commonly used in scleroderma clinical trials. METHODS: Ten researchers, members of a multicenter placebo controlled trial of methotrexate in early diffuse scleroderma, studied the intraobserver and interobserver variability of variables used to assess efficacy in scleroderma trials. RESULTS: For most measures, the variability within an observer was less than that found between observers, and therefore the intraobserver reliability was better than the interobserver reliability. The reliability of the modified Rodnan skin score exceeded the Rodnan skin score. Measures with inherent interpretation such as global assessments and skin scores had more variability than easily performed measurements such as grip strength and oral opening. CONCLUSION: Some of our variability was higher than variability previously reported; this could be due to the large number of examiners and patients in our study.
Authors: N Bellamy; C Anjema; T Chhina; N Dudek; B Hurley; B Landesman; L Probyn; J Hill; J Campbell Journal: Inflammopharmacology Date: 1999 Impact factor: 4.473
Authors: Taeyoung Kang; Giuseppina Abignano; Giovanni Lettieri; Richard J Wakefield; Paul Emery; Francesco Del Galdo Journal: Eur J Rheumatol Date: 2014-09-01
Authors: Dinesh Khanna; Daniel E Furst; Philip J Clements; Yannick Allanore; Murray Baron; Lazlo Czirjak; Oliver Distler; Ivan Foeldvari; Masataka Kuwana; Marco Matucci-Cerinic; Maureen Mayes; Thomas Medsger; Peter A Merkel; Janet E Pope; James R Seibold; Virginia Steen; Wendy Stevens; Christopher P Denton Journal: J Scleroderma Relat Disord Date: 2017 Jan-Apr
Authors: Tamás Constantin; Ivan Foeldvari; Clare E Pain; Annamária Pálinkás; Peter Höger; Monika Moll; Dana Nemkova; Lisa Weibel; Melinda Laczkovszki; Philip Clements; Kathryn S Torok Journal: Eur J Pediatr Date: 2018-05-04 Impact factor: 3.183
Authors: N Bellamy; C Anjema; N Alikhan; T Chhina; D Dhanoa; D Edelist; Z Esufali; F Ismail; J Hill; J Campbell Journal: Inflammopharmacology Date: 1999 Impact factor: 4.473
Authors: N Bellamy; C Anjema; T S Frankovic; N Horowitz; G C Mills; S Shulman; C Smith; J Hill; J Campbell Journal: Inflammopharmacology Date: 1999 Impact factor: 4.473
Authors: N Bellamy; C Anjema; D Dhanoa; A Joglekar; G C Mills; G Nesrallah; C Smith; C Ucar; J Hill; J Campbell Journal: Inflammopharmacology Date: 1999 Impact factor: 4.473